Seelos Therapeutics, Inc. - Common Stock (SEEL)

Competitors to Seelos Therapeutics, Inc. - Common Stock (SEEL)

Axovant Gene Therapies Ltd.

Axovant focuses on gene therapies for neurological diseases, which overlaps with Seelos' efforts in novel therapies for disorders like Parkinson's disease and schizophrenia. Both companies aim to innovate treatments for complex neurological conditions, but Axovant has an advantage with its advanced gene therapy platform and collaborations with established academic institutions, providing it with a stronger pipeline of therapies in development.

Karuna Therapeutics, Inc.

Karuna Therapeutics is developing novel therapies for schizophrenia and other related psychiatric disorders, similar to Seelos' therapeutic goals. While both companies target the same market, Karuna has a more advanced clinical pipeline and strong backing from high-profile investors, which positions it well ahead of Seelos in bringing innovative treatments to market.

Neurocrine Biosciences, Inc. 

Neurocrine is focused on developing treatments for neurological and endocrine disorders, competing directly with Seelos in the market for conditions like tardive dyskinesia and other psychiatric disorders. Neurocrine has a strong track record of drug approvals and partnerships with larger pharmaceutical companies, providing it with greater financial resources and market credibility that Seelos currently lacks.

Sarepta Therapeutics, Inc. 

Sarepta specializes in precision genetic medicine aimed at treating rare diseases, particularly neuromuscular conditions, which aligns closely with Seelos' focus on developing novel therapeutics for serious neurological and psychiatric disorders. However, Sarepta has a more established product portfolio and significant revenue from commercially available therapies, giving it a competitive edge in experience and market presence over Seelos.

Supernus Pharmaceuticals, Inc. 

Supernus Pharmaceuticals develops treatments for central nervous system disorders, including epilepsy and attention deficit hyperactivity disorder (ADHD), and while Seelos also targets CNS conditions, Supernus has a more established presence and a robust portfolio of FDA-approved drugs, which gives it a competitive advantage in terms of established sales and market presence.